Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
Iovance Biotherapeutics (IOVA) appointed Noah Berkowitz as Chief Medical Officer, effective September 30, 2026, as it prepares for development and regulatory milestones.
Berkowitz previously served as Chief Medical Officer at Arvinas Pharmaceuticals and led hematology development at Bristol Myers Squibb, where his teams achieved approvals for the cell therapies Abecma and Breyanzi.
In connection with the appointment, Iovance granted stock options and restricted stock units covering up to 450,000 common shares on September 30, 2026. Options have a $14.82 exercise price. Awards vest over three years: one-third on the first anniversary of his start date, then eight quarterly installments. Certain restricted stock units may instead vest upon specified regulatory milestones. Vesting requires continued employment through the applicable dates.
Iovance Biotherapeutics (IOVA) raised its full-year 2026 total revenue guidance to $410 million to $420 million.
The range replaces prior guidance of $350 million to $370 million. The new midpoint is $55 million, or approximately 15%, higher than the previous midpoint and implies nearly 60% annual growth in total revenue. Iovance attributed the increase to U.S. demand for Amtagvi and Proleukin. The company reported record second-quarter 2026 total product revenue of $99.3 million and has completed the guidance review announced with those results.
Iovance expects to report third-quarter 2026 financial results in early November 2026. The company said current patient demand and its manufacturing schedule give it visibility into third- and fourth-quarter revenue.
Iovance Biotherapeutics (IOVA) approved inducement stock options on September 17, 2026 for eighteen new non-executive employees covering an aggregate of 179,750 shares of common stock.
The options were granted under the company’s Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $10.02, equal to the closing price of Iovance’s common stock on the grant date. The awards vest over three years: one-third of the shares vest on the first anniversary of each employee’s start date, and the remaining shares vest in eight quarterly installments over the following two years, subject to continued employment through each vesting date.
Iovance Biotherapeutics (IOVA)/b) announced that senior leadership will present at two investor conferences in September 2026.The company will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 11:00 a.m. ET in Boston, MA, and deliver a presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 4:00 p.m. ET in New York, NY. A live and archived webcast of both events will be available on the company’s investor relations website.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on August 20, 2026, covering an aggregate of 240,135 shares of common stock for twenty new non-executive employees. The options were granted under the company’s Amended and Restated 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $8.99, equal to the closing price of Iovance’s common stock on the grant date. The awards vest over three years: one-third on the first anniversary of each employee’s start date, and the remaining two-thirds in eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) reported record 2Q26 product revenue of approximately $99.3 million, up 66% year-over-year and 39% sequentially, driven by about $91 million in U.S. Amtagvi sales and ~$9 million in global Proleukin revenue. Gross margin (excluding depreciation and amortization) increased to 56%, supported by higher volume and internal manufacturing efficiencies.
The company reduced R&D expenses by roughly 6% versus 1Q26 and narrowed its quarterly net loss to $47.3 million from $111.7 million a year earlier. Iovance is reviewing its 2026 revenue guidance of $350–$370 million and expects further margin improvements. Regulatory highlights include Australian approval of Amtagvi, U.K. and Swiss marketing applications in review, and U.S. FDA Fast Track Designation for lifileucel in soft tissue sarcomas and non-squamous NSCLC. Iovance ended June 30, 2026 with a cash position of about $304 million, which is expected to fund operations into the second half of 2028.
Iovance Biotherapeutics (NASDAQ: IOVA) announced it will host a conference call and live audio webcast on Thursday, August 6, 2026 at 8:30 a.m. ET to report its second quarter 2026 financial results and provide corporate updates. Investors can access the live or archived webcast by registering at the provided Media Server link or via the Investors section of IR.Iovance.com. The archived webcast will be available for one year.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options for seventeen new non-executive employees on July 16, 2026. The options cover an aggregate of 139,930 common shares under the Amended and Restated 2021 Inducement Plan, with an exercise price of $4.66 per share, equal to the closing price on the grant date. Each option vests over three years: one-third on the first anniversary of the employee’s start date, and the remaining two-thirds in eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) granted inducement stock options on June 18, 2026 to twenty-seven new non-executive employees. The options cover an aggregate 140,860 shares of common stock under the 2021 Inducement Plan, have a $3.91 exercise price, and vest over three years.
Iovance Biotherapeutics (NASDAQ: IOVA) received conditional approval from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat adults with unresectable or metastatic melanoma after prior PD-1 and, if BRAF V600 positive, targeted therapy.
This is Amtagvi’s third marketing authorization and the first T cell therapy for a solid tumor cancer in Australia.